Biphenyl

Biphenyl

SCHEMBL8168014

CC(=O)O[SiH2]OC(C)=O.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
BACE1 P56817 1/20 0.43
ALDH1A1 P00352 3/20 0.42
GAA P10253 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
PTGS2 P35354 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.39
PTGS1 P23219 2/20 0.39
ELANE P08246 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28650304 0.90 BACE1 (0.47) SMN1; SMN2MAPTBACE1ALDH1A1PTGS2
SCHEMBL28295624 0.83 MCL1 (0.44) SMN1; SMN2MAPTBACE1ALDH1A1L3MBTL1
Biphenyl SCHEMBL27640086 0.79 MAPT (0.44) SMN1; SMN2MAPTBACE1ALDH1A1GAA
Biphenyl SCHEMBL6269566 0.78 MAPT (0.56) SMN1; SMN2MAPTBACE1ALDH1A1GAA
Biphenyl SCHEMBL27819830 0.78 SMN1; SMN2 (0.56) SMN1; SMN2MAPTBACE1ALDH1A1CYP2C19
Biphenyl SCHEMBL8773175 0.78 SMN1; SMN2 (0.56) SMN1; SMN2MAPTBACE1ALDH1A1GAA
Biphenyl SCHEMBL1822628 0.77 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9
Biphenyl SCHEMBL29059196 0.77 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9
Biphenyl SCHEMBL538359 0.77 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9
Biphenyl SCHEMBL15332958 0.77 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104609738-A Method used for increasing silicon dioxide antireflection film hole stability GEN RES INST NONFERROUS METALS 2015-05-13 CN claimed
CN-1764705-B Process for the preparation of poly(silyl ester)s, and their uses SIGMAKALON B V 2010-09-01 CN claimed
CN-1764705-A Process for the preparation of poly(silyl ester)s, and their uses SIGMAKALON B V (NL) 2006-04-26 CN claimed
CN-1615332-A Antireflective coatings for photolithography and methods of making the same HONEYWELL INT INC (US) 2005-05-11 CN claimed
CN-1096433-C Mixture for treating silicon-containing substrates SHEMITAL AG (DE) 2002-12-18 CN claimed
US-6030444-A Mixture for treating silicon-containing substrates METALLGESELLSCHAFT AKTIENGESELLSCHAFT (DE) 2000-02-29 US claimed
EP-0783464-B1 MIXTURE FOR TREATING SILICON-CONTAINING SUBSTRATES METALLGESELLSCHAFT AG (DE) 1998-03-18 EP claimed
CN-1158596-A Mixture for treating silicon-containing substrates METALLGESELLSCHAFT AG (DE) 1997-09-03 CN claimed
US-12624168-B2 Methods for making polyfunctional organosiloxanes and compositions containing same DOW SILICONES CORPORATION (US) 2026-05-12 US disclosed
US-12534650-B2 Composition for preparing a release coating and method of preparing coated substrate DOW SILICONES CORPORATION (US) 2026-01-27 US disclosed
EP-4519346-B1 SILICONE-POLYETHER COPOLYMER, SEALANTS COMPRISING SAME, AND RELATED METHODS DOW SILICONES CORP (US) 2026-01-14 EP disclosed
EP-3645607-B1 METHOD FOR HYDROSILYLATION OF ALIPHATICALLY UNSATURATED ALKOXYSILANES AND HYDROGEN TERMINATED ORGANOSILOXANE OLIGOMERS TO PREPARE ALKOXYSILYL TERMINATED POLYMERS USEFUL FOR FUNCTIONALIZING POLYORGANOSILOXANES USING AN IRIDIUM CATALYST DOW SILICONES CORP (US) 2025-11-05 EP disclosed
US-12428561-B2 Silicone-polyether copolymer, sealants comprising same, and related methods DOW SILICONES CORPORATION (US) 2025-09-30 US disclosed
EP-4608885-A1 COMPOSITION FOR PREPARING A RELEASE COATING AND METHOD OF PREPARING COATED SUBSTRATE Dow Silicones Corporation (US) 2025-09-03 EP disclosed
EP-0520279-B1 Multilayer structures containing block copolymers of polysiloxanes and copolymers of conjugated dienes and aromatic vinyl compounds BRIDGESTONE CORP (JP) 1998-08-12 EP disclosed
EP-0832912-A2 Block copolymers of polysiloxanes and copolymers of conjugated dienes and aromatic vinyl compounds, and multilayer structures containing same Bridgestone Corporation (JP) 1998-04-01 EP disclosed
CN-1158596-A Mixture for treating silicon-containing substrates METALLGESELLSCHAFT AG (DE) 1997-09-03 CN disclosed
US-5552483-A Block copolymers of polysiloxanes and copolymers of conjugated dienes and aromatic vinyl compounds, and multilayer structures containing same BRIDGESTONE CORPORATION (JP) 1996-09-03 US disclosed
US-5260123-A Exhibits both surface release characteristics and elastomeric properties BRIDGESTONE CORPORATION (JP) 1993-11-09 US disclosed
EP-0520279-A2 Block copolymers of polysiloxanes and copolymers of conjugated dienes and aromatic vinyl compounds, and multilayer structures containing same BRIDGESTONE CORPORATION (JP) 1992-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534650-B2 Composition for preparing a release coating and method of preparing coated substrate COL2A1, MSR1, COL1A1 SMN1; SMN2 154/4885MAPT 4657/4885BACE1 2035/4885
US-12624168-B2 Methods for making polyfunctional organosiloxanes and compositions containing same HAO2, H1-2, HRH2 SMN1; SMN2 1484/4885MAPT 4732/4885BACE1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.